Prognostic significance of c-KIT in vulvar cancer: bringing this molecular marker from bench to bedside
Tóm tắt
Vulvar carcinomas are rare tumors, and there is limited data regarding molecular alterations. To our knowledge there are no published studies on c-KIT and squamous cell carcinomas of the vulva (VSCC). Although there are a significant number of other tumor types which express c-KIT, there remains controversy as to its relationship to patient outcome. Thus, we wished to investigate such controversial findings to determine the prognostic importance of c-KIT by evaluating its protein and mRNA expression in VSCCs, correlating these findings with clinicopathological features and Human Papillomavirus (HPV) infection. c-KIT expression was scored by immunohistochemistry (IHC) as positive or negative in 139 formalin-fixed paraffin-embedded (FFPE) cases of vulvar carcinomas arrayed in a tissue microarray (TMA) using the DAKO® A4502 rabbit polyclonal c-KIT antibody (diluted 1:100). c-KIT mRNA was evaluated by qRT-PCR in 34 frozen samples from AC Camargo Hospital Biobank (17 tumoral and 17 non-tumoral samples) using TaqMan probes–Applied Biosystems [Hs00174029_m1]. HPV genotyping was assessed in 103 samples using Linear Array® HPV Genotyping Test kit (Roche Molecular Diagnostics, Basel, Switzerland). All results obtained were correlated with clinical and pathological data of the patients. c-KIT protein was positive by immunohistochemistry in 70.5% of the cases and this was associated with a higher global survival (p = 0.007), a higher recurrence-free survival (p < 0.0001), an absence of associated lesions (p = 0.001), lymph node metastasis (p = 0.0053), and HPV infection (p = 0.034). Furthermore, c-KIT mRNA quantitation revealed higher levels of transcripts in normal samples compared to tumor samples (p = 0,0009). Our findings indicate that those vulvar tumors staining positively for c-KIT present better prognosis. Thus, positivity of c-KIT as evaluated by IHC may be a good predictor for use of more conservative surgery techniques and lymph node dissection in vulvar cancer. So part of the essence of our study is to see the possibility of translating our current results from the bench to the bedside. This will help provide patients a more appropriate, less mutilating treatment, in order to keep the maximum physical and psychic quality as possible to these women.
Tài liệu tham khảo
Buxant F, Anaf V, Haouari H: Rapid Groin Recurrence of a vulvar carcinoma with invasion of the femoral vessels and the importance of the inicial groin dissection in the staging surgery. Acta Chir Belg. 2005, 105: 418-419.
Stroup AM, Harlan LC, Trimble EL: Demographic, clinical, and treatment trends among women diagnosed with vulvar cancer in the U.S. Gynecol Oncol. 2008, 108 (Suppl 3): 577-583.
Vulvar Cancer Key Statistics: American Cancer Society. http://www.cancer.org/Cancer/VulvarCancer/DetailedGuide/vulvar-cancer-key-statistics Last updated: 03/13/2012. Accessed on: 07/26/2012
Jones RW, Baranyai J, Stables S: Trends in squamous cell carcinoma of the vulva: the influence of vulvar intraepithelial neoplasia. Obstet Gynecol. 1997, 90: 448-452. 10.1016/S0029-7844(97)00298-6.
Lanneau GS, Argenta PA, Lanneau MS: Vulvar cancer in young women: demographic features and outcome evaluation. Am J Obstet Gynecol. 2009, 200: 645-
Joura EA, Losch A, Haider-Angeler MG: Trends in vulvar neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women. J Reprod Med. 2000, 45: 613-615.
Berchuck A, Rodriguez G, Kamel A: Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina. Obstet Gynecol. 1990, 76: 381-387.
Maeda H, Yamagata A, Nishikawa S: Requirement of c-KIT for development of intestinal pacemaker system. Development. 1992, 116: 369-375.
Krams M, Parwaresch R, Sipos B: Expression of the c-KIT receptor characterizes a subset of neuroblastomas with favorable prognosis. Oncogene. 2004, 23: 588-595. 10.1038/sj.onc.1207145.
Tsuura Y, Hiraki H, Watanabe K: Preferential localization of c-KIT product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: immunohistochemical study on formalin-fixed, paraffin-embedded tissues. Virchows Arch. 1994, 424: 135-141.
Maffini MV, Soto AM, Sonnenschein C: Lack of c-KIT receptor promotes mammary tumors in N-nitrosomethylurea-treated Ws/Ws rats. Cancer Cell Int. 2008, 8: 5-10.1186/1475-2867-8-5.
Sperling C, Schwartz S, Buchner T: Expression of the stem cell factor receptor c-KIT (CD117) in acute leukemias. Haematologica. 1997, 82: 617-621.
Lev S, Blechman JM, Givol D, Yarden Y: Steel factor and c-KIT protooncogene: genetic lessons in signal transduction. Crit Rev Oncog. 1994, 5: 141-168. 10.1615/CritRevOncog.v5.i2-3.30.
Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM: Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998, 152: 1259-1269.
Makhlouf HR, Remotti HE, Ishak KG: Expression of KIT (CD117) in angiomyolipoma. Am J Surg Pathol. 2002, 26: 493-497. 10.1097/00000478-200204000-00012.
Schwartz S, Heinecke A, Zimmermann M: Expression of the C-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance. Leuk Lymphoma. 1999, 34: 85-94.
Hines SJ, Organ C, Kornstein MJ, Krystal GW: Coexpression of the c-KIT and stem cell factor genes in breast carcinomas. Cell Growth Differ. 1995, 6: 769-779.
Heinrich MC, Blanke CD, Druker BJ, Corless CL: Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol. 2002, 20: 1692-1703. 10.1200/JCO.20.6.1692.
di Paola RS, Kuczynski WI, Onodera K: Evidence for a functional kit receptor in melanoma, breast, and lung carcinoma cells. Cancer Gene Ther. 1997, 4: 176-182.
Bar-Sela G, Ben Arush MW, Sabo E: Pediatric nasopharyngeal carcinoma: better prognosis and increased c-Kit expression as compared to adults. Pediatr Blood Cancer. 2005, 45: 291-297. 10.1002/pbc.20264.
Bataille R, Pellat-Deceunynck C, Robillard N: CD117 (c-KIT) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis. Leuk Res. 2008, 32: 379-382. 10.1016/j.leukres.2007.07.016.
Hasigawa T: Role of immunohistochemical expression of KIT/CD 117 in gastrointestinal stromal tumors. Handbook of immunohistochemistry and in situ hybridization of human carcinomas. Edited by: Hayat MA. 2006, San Diego: Elsevier Academic Press, 135-142.
Inoue M, Kyo S, Fujita M: Coexpression of the c-KIT receptor and the stem cell factor in gynecological tumors. Cancer Res. 1994, 54: 3049-3053.
Huang S, Luca M, Gutman M: Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. Oncogene. 1996, 13: 2339-2347.
Eroğlu A, Sarı A, Eroglu N: Primary epithelioid sarcoma of the vulva in pregnancy. Gynecol Surg. 2008, 5: 61-64. 10.1007/s10397-007-0316-3.
Jahn T, Seipel P, Coutinho S: Analysing c-KIT internalization using a functional c-KIT-EGFP chimera containing the uorochrome within the extracellular domain. Oncogene. 2002, 21: 4508-4520. 10.1038/sj.onc.1205559.
Rouzier R, Haddad B, Plantier F: Local relapse in patients treated for squamous cell vulvar carcinoma: incidence and prognostic value. Obstet Gynecol. 2002, 100: 1159-1167. 10.1016/S0029-7844(02)02501-2.
Caruana G, Cambareri AC, Ashman LK: Isoforms of c-KIT differ in activation of signalling pathways and transformation of NIH3T3 fibroblasts. Oncogene. 1999, 18: 5573-5581. 10.1038/sj.onc.1202939.
Kapur R, Cooper R, Zhang L, Williams DA: Cross-talk between alpha(4)beta(1)/alpha(5)beta(1) and c-Kit results in opposing effect on growth and survival of hematopoietic cells via the activation of focal adhesion kinase, mitogen-activated protein kinase, and Akt signaling pathways. Blood. 2001, 97: 1975-1981. 10.1182/blood.V97.7.1975.
Natali PG, Nicotra MR, Sures I: Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Res. 1992, 52 (Suppl 22): 6139-6143. 15
de Hullu JA, van der Zee AG: Surgery and radiotherapy in vulvar cancer. Crit Rev Oncol Hematol. 2006, 60: 38-58. 10.1016/j.critrevonc.2006.02.008.
Holschneider CH, Berek JS: Câncer de vulva. Tratado de ginecologia. Edited by: Berek JS. 2002, Rio de Janeiro: Guanabara Koogan, 1234-1262. in portuguese
Kumar S, Shah JP, Bryant CS: A comparison of younger vs older women with vulvar cancer in the United States. Am J Obstet Gynecol. 2009, 200: 52-55. 10.1016/j.ajog.2008.09.869.